Legend Biotech Corp Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes
Legend Biotech Corp (LEGN) reported Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes of -$26.00 million for the 6-month period ending 2025-06-30, per its 6-K filed 2025-08-11.
Financial Statements › Notes
ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges · last filed 2025-08-11
- Legend Biotech Corp increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2025-03-31 was $153.55M.
- Legend Biotech Corp increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2024-03-31 was -$379.80M.
- Legend Biotech Corp increase decrease in cash and cash equivalents before effect of exchange rate changes for the quarter ending 2023-03-31 was -$123.63M.
| Period end | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 3 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 6 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 9 month | Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$26.00M 6-K · filed 2025-08-11 | |||
| 2025-03-31 | $153.55M 6-K · filed 2025-05-13 | |||
| 2024-12-31 | -$988.88M 20-F · filed 2025-03-11 | |||
| 2024-09-30 | -$818.63M 6-K · filed 2024-11-12 | |||
| 2024-06-30 | -$1.08B 6-K · filed 2025-08-11 | |||
| 2024-03-31 | -$379.80M 6-K · filed 2025-05-13 | |||
| 2023-12-31 | $491.00M 20-F · filed 2025-03-11 | |||
| 2023-09-30 | $178.21M 6-K · filed 2024-11-12 | |||
| 2023-06-30 | $447.17M 6-K · filed 2024-08-09 | |||
| 2023-03-31 | -$123.63M 6-K · filed 2024-05-13 | |||
| 2022-12-31 | $99.60M 20-F · filed 2025-03-11 | |||
| 2022-09-30 | $125.20M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | -$308.31M 6-K · filed 2023-08-15 | |||
| 2021-12-31 | $233.22M 20-F · filed 2024-03-19 | |||
| 2021-06-30 | $31.81M 6-K · filed 2021-08-23 | |||
| 2020-12-31 | $371.70M 20-F · filed 2023-03-30 | |||
| 2020-06-30 | $479.17M 6-K · filed 2021-08-23 | |||
| 2019-12-31 | -$127.05M 20-F/A · filed 2023-02-17 | |||
| 2018-12-31 | $207.93M 20-F · filed 2021-04-02 |